Earnings Call Insights: SUI Group Holdings Limited (SUIG) Q4 2025 Management View Marius Barnett emphasized a maturing digital asset industry, highlighting “the regulatory engagement in the United States has shifted from an uncertainty towards structure” and described recent board strengthening with the appointment
Earnings Call Insights: SUI Group Holdings Limited (SUIG) Q4 2025 Management View Marius Barnett emphasized a maturing digital asset industry, highlighting “the regulatory engagement in the United States has shifted from an uncertainty towards structure” and described recent board strengthening with the appointment
Earnings Call Insights: Monster Beverage Corporation (MNST) Q4 2025 Management View CEO Hilton Schlosberg announced new roles for Rob Gehring, Guy Carling, and Emelie Tirre, attributing ongoing success to their contributions. Schlosberg stated, "We are pleased to report another quarter of strong financial results and
Earnings Call Insights: Monster Beverage Corporation (MNST) Q4 2025 Management View CEO Hilton Schlosberg announced new roles for Rob Gehring, Guy Carling, and Emelie Tirre, attributing ongoing success to their contributions. Schlosberg stated, "We are pleased to report another quarter of strong financial results and
smileitsmccheeze/iStock via Getty Images Innovative Industrial Properties ( IIPR ) just released Q4 and full-year 2025 earnings. With tenant defaults in 2025 and cannabis rescheduling uncertain, the share price remains depressed, but I think the valuation is finally attractive. Summary of Previous
smileitsmccheeze/iStock via Getty Images Innovative Industrial Properties ( IIPR ) just released Q4 and full-year 2025 earnings. With tenant defaults in 2025 and cannabis rescheduling uncertain, the share price remains depressed, but I think the valuation is finally attractive. Summary of Previous
The weight loss-fueled gains of Danish drugmaker Novo Nordisk A/S are officially a thing of the past. The stock this week wiped out the last of the yearslong surge that followed the 2021 US approval of its Wegovy obesity drug, after a next-generation shot delivered less weight loss than that of its main rival. Down 21%, the shares are on track for their steepest weekly slump since August, surpassi...
The weight loss-fueled gains of Danish drugmaker Novo Nordisk A/S are officially a thing of the past. The stock this week wiped out the last of the yearslong surge that followed the 2021 US approval of its Wegovy obesity drug, after a next-generation shot delivered less weight loss than that of its main rival. Down 21%, the shares are on track for their steepest weekly slump since August, surpassing one of 20% earlier this month that followed a dire sales forecast . The setback caps a tumultuous five years for Novo, a period that saw the stock ride a wave of optimism driven by its leadership in the booming obesity-drug market. Less than two years have been enough to unravel those roughly fivefold gains, and Chief Executive Officer Mike Doustdar now faces mounting calls to diversify beyond diabetes and obesity — franchises that have defined the company for three decades. Following this week’s update, the whole thesis for Novo now relies on Wegovy pills, according to Intron Health analyst Naresh Chouhan . Last month’s launch was one of the most successful pharmaceutical debuts ever with more than 240,000 Americans taking the pill already, Doustdar said. “If there is any sign of a material slowdown from what has clearly been an excellent launch, we expect the shares to further de-rate,” Chouhan said. Read More: Novo Next-Generation Obesity Shot Falls Short of Lilly Rival For some bullish analysts, this week’s disappointing data for Novo’s next-generation obesity shot CagriSema was the last straw, with five downgrading the stock. Deutsche Bank AG’s Emmanuel Papadakis cut his rating to hold, saying the results blow a sizable hole in the investment case for the drug. JPMorgan Chase & Co.’s Richard Vosser also downgraded the shares to neutral, saying the latest developments are likely to curb the drug’s commercial potential. Read More: Novo’s Latest Obesity Flop Prompts Investors to Call for a Pivot To be sure, Novo’s obesity shot still delivered 20.2% weight loss, not far...
光本位科技与百度智能云举行战略合作签约仪式。双方基于文心快码联合推出针对于光电芯片开发流程的全栈 AI 研发解决方案 Lightmate ,以 AI Agent 为技术核心重构光计算芯片研发流程。同时,双方围绕联合技术研发、研发工具链集成及产业生态拓展等多维度展开深度协同,推动光计算技术从实验室走向工业化标准落地,助力国产算力自主可控建设。据悉,光本位科技已实现光计算系统的商业化交付。(科创板日报...
光本位科技与百度智能云举行战略合作签约仪式。双方基于文心快码联合推出针对于光电芯片开发流程的全栈 AI 研发解决方案 Lightmate ,以 AI Agent 为技术核心重构光计算芯片研发流程。同时,双方围绕联合技术研发、研发工具链集成及产业生态拓展等多维度展开深度协同,推动光计算技术从实验室走向工业化标准落地,助力国产算力自主可控建设。据悉,光本位科技已实现光计算系统的商业化交付。(科创板日报)
我是一个和大家一样,一直在思考的人。就像今天开场时主持人和几位朋友讲的,几乎所有人其实都在想这件事:正在发生什么,改变了什么,我们需要坚持什么,以及我们能做些什么。 几个礼拜前,腾讯研究院的朋友看到我写的一篇小笔记,标题叫《真正的重建从不仰望 AI 开始》,希望我能围绕这个主题谈一谈。我认为这个思考角度要破题,需要更宽广、更深切的一种厚度,所以我加了一个附题:《走出恍惚——科技思潮的社会光谱与创世...
The European Union will provisionally apply its trade deal with the Mercosur group of South American countries, overriding concern from some lawmakers who have sent the deal for a test at the bloc’s top court. Ursula von der Leyen , who leads the bloc’s executive arm as European Commission president, justified the move, saying the deal “gives Europe a strategic first mover advantage in a world of ...
The European Union will provisionally apply its trade deal with the Mercosur group of South American countries, overriding concern from some lawmakers who have sent the deal for a test at the bloc’s top court. Ursula von der Leyen , who leads the bloc’s executive arm as European Commission president, justified the move, saying the deal “gives Europe a strategic first mover advantage in a world of sharp competition and short horizons.” “Provisional application is, by its nature, provisional,” von der Leyen added. “The agreement can only be fully concluded once the European Parliament has given its consent.” The announcement comes as Argentina and Uruguay ratified the deal, a move that was hailed by European Council President Antonio Costa . Brazil and Paraguay are the other two members of the Mercosur group which signed the deal with the EU. The EU and Mercosur clinched one of the world’s largest free-trade agreements in January after 25 years of negotiations. The pact will create an integrated market of 780 million consumers and strengthen Europe’s foothold in a resource-rich region that’s increasingly contested by the US and China . Read More: EU Inks South America Trade Deal After 25 Years of Negotiations The deal has faced fierce opposition in Europe from countries with significant farming industries. French President Emmanuel Macron was among those who apposed the deal, though a majority of EU countries backed it, paving the way for its ratification. The deal still faces a hurdle at the EU’s top court, after lawmakers in the bloc’s parliament voted to submit it for a judicial review.